118 related articles for article (PubMed ID: 3645704)
1. Cisplatin: outpatient and office hydration regimen.
Goodman M
Semin Oncol Nurs; 1987 Feb; 3(1 Suppl):36-45. PubMed ID: 3645704
[No Abstract] [Full Text] [Related]
2. Considerations in the outpatient and office administration of cisplatin.
Miller SA
Semin Oncol Nurs; 1987 Feb; 3(1 Suppl):3-7. PubMed ID: 3645703
[No Abstract] [Full Text] [Related]
3. Safe and effective two-hour outpatient regimen of hydration and diuresis for the administration of cis-diamminedichloroplatinum (II).
Vogl SE; Zaravinos T; Kaplan BH; Wollner D
Eur J Cancer (1965); 1981 Mar; 17(3):345-50. PubMed ID: 6790287
[No Abstract] [Full Text] [Related]
4. Hydration regimen and hematological toxicity of a cisplatin-based chemotherapy regimen. Clinical observations and pharmacokinetic analysis.
Numico G; Benasso M; Vannozzi MO; Merlano M; Rosso R; Viale M; Esposito M
Anticancer Res; 1998; 18(2B):1313-8. PubMed ID: 9615808
[TBL] [Abstract][Full Text] [Related]
5. An Outpatient, Dose-Intense, Intravenous Cisplatin and Oral Etoposide Regimen for the Treatment of Advanced, Platinum-Resistant Ovarian Cancer.
Morgan RD; Clamp AR; Hasan J; Mitchell C; Saunders G; Mescallado N; Welch R; Jayson GC
Int J Gynecol Cancer; 2018 Mar; 28(3):448-452. PubMed ID: 29466253
[TBL] [Abstract][Full Text] [Related]
6. Cisplatin hydration with and without mannitol diuresis in refractory disseminated malignant melanoma: a southwest oncology group study.
Al-Sarraf M; Fletcher W; Oishi N; Pugh R; Hewlett JS; Balducci L; McCracken J; Padilla F
Cancer Treat Rep; 1982 Jan; 66(1):31-5. PubMed ID: 6796269
[TBL] [Abstract][Full Text] [Related]
7. Effects of fluid manipulation on the incidence of vomiting during outpatient cisplatin infusion.
Jordan LN
Oncol Nurs Forum; 1989; 16(2):213-8. PubMed ID: 2928270
[TBL] [Abstract][Full Text] [Related]
8. Pharmacokinetic-Pharmacodynamic Analysis of Cisplatin with Hydration and Mannitol Diuresis: The Contribution of Urine Cisplatin Concentration to Nephrotoxicity.
Fukushima K; Okada A; Oe H; Hirasaki M; Hamori M; Nishimura A; Shibata N; Sugioka N
Eur J Drug Metab Pharmacokinet; 2018 Apr; 43(2):193-203. PubMed ID: 28913815
[TBL] [Abstract][Full Text] [Related]
9. Considerations with cisplatin (Platinol) administration in the office setting for oncology nurses.
Griffin J
Semin Oncol Nurs; 1987 Feb; 3(1 Suppl):8-15. PubMed ID: 3031794
[No Abstract] [Full Text] [Related]
10. Outpatient and office administration of cisplatin.
Semin Oncol Nurs; 1987 Feb; 3(1 Suppl):1-45. PubMed ID: 3645701
[No Abstract] [Full Text] [Related]
11. Renal protective effect of a hydration supplemented with magnesium in patients receiving cisplatin for head and neck cancer.
Kimura T; Ozawa T; Hanai N; Hirakawa H; Suzuki H; Hosoi H; Hasegawa Y
J Otolaryngol Head Neck Surg; 2018 Feb; 47(1):10. PubMed ID: 29394952
[TBL] [Abstract][Full Text] [Related]
12. Disorders of serum electrolytes and renal function in patients treated with cis-platinum on an outpatient basis.
Giaccone G; Donadio M; Ferrati P; Ciuffreda L; Bagatella M; Gaddi M; Calciati A
Eur J Cancer Clin Oncol; 1985 Apr; 21(4):433-7. PubMed ID: 4040022
[TBL] [Abstract][Full Text] [Related]
13. Comparison of oral and intravenous hydration and diuretic, choice for protecting cisplatin induced nephrotoxicity.
Dana R; Kachhwaha VS
Indian J Cancer; 1996 Dec; 33(4):168-70. PubMed ID: 9254992
[TBL] [Abstract][Full Text] [Related]
14. High-dose cisplatin therapy using mannitol versus furosemide diuresis: comparative pharmacokinetics and toxicity.
Ostrow S; Egorin MJ; Hahn D; Markus S; Aisner J; Chang P; LeRoy A; Bachur NR; Wiernik PH
Cancer Treat Rep; 1981; 65(1-2):73-8. PubMed ID: 6784924
[TBL] [Abstract][Full Text] [Related]
15. [Usefulness of oral rehydration solution for hydration in cancer chemotherapy: toward the application of outpatient chemotherapy with high-dose Cisplatin therapy-].
Sato J; Kudo K; Hino K; Takahashi K
Gan To Kagaku Ryoho; 2011 Sep; 38(9):1471-6. PubMed ID: 21918344
[TBL] [Abstract][Full Text] [Related]
16. [Toxicity of cisplatin administered with hydration of 1-hour duration and forced diuresis].
Lopez M; Papaldo P; Perno CF; Di Lauro L; Barduagni A
Clin Ter; 1983 Nov; 107(3):207-13. PubMed ID: 6686503
[No Abstract] [Full Text] [Related]
17. Modification of the renal toxicity of cis-dichlorodiammineplatinum(II) with furosemide in male F344 rats.
Ward JM; Grabin ME; LeRoy AF; Young DM
Cancer Treat Rep; 1977; 61(3):375-9. PubMed ID: 872137
[No Abstract] [Full Text] [Related]
18. Feasibility and safety of a modified outpatient regimen with intravenous/intraperitoneal chemotherapy for optimally debulked stage III ovarian cancer.
Bruixola G; Domingo S; Díaz R; Caballero J; Palomar L; De La Cueva H; Santaballa A
Int J Gynecol Cancer; 2015 Feb; 25(2):214-21. PubMed ID: 25415075
[TBL] [Abstract][Full Text] [Related]
19. A phase I study of S-1 combined with weekly cisplatin for metastatic gastric cancer in an outpatient setting.
Hyodo I; Nishina T; Moriwaki T; Endo S; Terao T; Hirao K; Nasu J; Hirasaki S; Endo H; Masumoto T; Tajiri H; Kurita A
Eur J Cancer; 2003 Nov; 39(16):2328-33. PubMed ID: 14556924
[TBL] [Abstract][Full Text] [Related]
20. A short outpatient hydration schedule for cisplatin administration.
Al Bahrani BJ; Moylan EJ; Forouzesh B; Della-Fiorentina SA; Goldrick AJ
Gulf J Oncolog; 2009 Jan; (5):30-6. PubMed ID: 20084783
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
